DS
CRXT

David Shaw’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

David Shaw’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-27,118
Closed -$273K – 5492
2021
Q2 		$273K Buy
+27,118
New +$273K ﹤0.01% 4322

Other funds holding CRXT

BCL
Bracebridge Capital LLC Boston, Massachusetts $5.53B AUM 25.79% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $317M AUM 26.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

David Shaw's CRXT Position: Q3 2021 in Review

David Shaw sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2021, closing a stake of 27,118 shares — an estimated $273K sold.

David Shaw first reported a position in CRXT in Q2 2021 and held it in 1 quarter. The position peaked at $273K in Q2 2021. 12 funds tracked by Wall St. Rank hold CRXT as of Q3 2021.

  • David Shaw reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • David Shaw sold 27,118 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2021, an estimated $273K.
  • David Shaw first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • David Shaw's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $273K in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.